Search
Scientists Found a Hidden Immune Organ Inside the Human Skull — What It Means for Brain Cancer Treatment and Regulatory Affairs
Scientists at Washington University School of Medicine in St. Louis have identified a **skull immune organ** — lymphoid structures inside the skull's bone marrow that act as first responders to brain disease. Published in *Nature* on 19 August 2026, the study shows microscopic channels carry antigens from the brain into skull marrow, where **T follicular helper cells** train **B cells** to fight threats, including glioblastoma, before distant lymph nodes react. Similar cells
Aug 2812 min read
FDA's Streamlined Nonclinical Safety Guidance for Monoclonal Antibodies: What It Means for Regulatory Affairs Professionals in 2026
In December 2025, the US Food and Drug Administration (FDA) published draft guidance — "Monoclonal Antibodies: Streamlined Nonclinical Safety Studies" (Docket FDA-2025-D-4634) — recommending that sponsors of monospecific monoclonal antibodies (mAbs) can reduce or eliminate long-duration animal toxicology studies, including in nonhuman primates (NHPs), where a robust weight-of-evidence (WoE) risk assessment supports doing so. It affects any company developing single-target mAb
Aug 2511 min read
Overqualified but Under-Skilled: How PhDs and Postdocs Can Pivot Into Regulatory Affairs Careers
A PhD to regulatory affairs career change is one of the most viable moves available to scientists who find the academic job market unable to absorb them. Vitae's 2026 tracking data shows that although 91% of UK doctoral graduates are employed, 41% remain in higher education roles, 93% of which are on fixed-term contracts. Regulatory affairs offers permanent, well-paid, office-based roles that value scientific rigour — but PhDs typically lack the submission-specific skills (CT
Aug 1912 min read
We Analysed 196 Regulatory Affairs Career Changers — Here's What Actually Predicts Success
A regulatory affairs career change success analysis of 196 course registrants found that only 16 people (8.2%) transitioned into a regulatory affairs role, and their profiles differ sharply from the wider group. This affects anyone considering a move into regulatory affairs — scientists, pharmacists, graduates and existing regulatory professionals. The data, collected between September 2024 and May 2026, shows that active job searching, existing regulatory or science experien
Aug 1810 min read
Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
Aug 1413 min read
eCTD 4.0 Explained: FDA, EMA and Japan Deadlines, Key Changes and What It Means for Regulatory Affairs Careers
**eCTD 4.0** is the next-generation global standard for electronic pharmaceutical regulatory submissions, replacing the document-centric **eCTD 3.2.2** format used since 2008. It affects regulatory affairs professionals, publishing specialists and every company submitting dossiers to the **FDA**, **EMA**, **PMDA** and other health authorities. The **FDA** has accepted eCTD 4.0 for new applications since **16 September 2024**; **Japan** targets a mandate by **April 2026**; and
Aug 1212 min read
The European Biotech Act 2026: What the New EU Biotechnology Framework Means for Pharma, Biotech and Regulatory Affairs Careers
The **European Biotech Act** is a European Commission legislative proposal, published as **COM(2025) 1022 final on 16 December 2025**, designed to close the EU's competitiveness gap in health biotechnology against the US and China. It affects pharmaceutical companies, biotech start-ups, investors and regulatory affairs professionals working with **ATMPs**, mRNA therapeutics, biologics and biosimilars. The Act introduces faster clinical trial timelines, EU-anchored investment
Aug 1212 min read
Regulatory Affairs Professional Stuck at the Same Level? Here's Why Most Regulatory Affairs Training Isn't Getting You Promoted
Regulatory affairs career progression stalls for most professionals not because they lack knowledge, but because their training and CV never move beyond execution-level tasks. Associates and specialists who have completed generic CPD courses, webinars or self-study modules often still cannot demonstrate ownership of a Marketing Authorisation Application (MAA) section, a variation classification decision, or a cross-region regulatory strategy — the exact evidence hiring panels
Aug 1011 min read
FDA's August 2026 PDUFA Wave: Five Landmark Decisions Regulatory Affairs Professionals Need to Know
The FDA PDUFA dates for August 2026 mark one of the busiest single-month regulatory windows of the year, with five separate Prescription Drug User Fee Act (PDUFA) decisions due between 5 and 28 August. The decisions affect a new mRNA influenza vaccine, an oral multiple myeloma therapy, a single-tablet HIV regimen, a radiopharmaceutical for neuroendocrine tumours, and a first-in-class treatment for an ultra-rare bone disorder. Sponsors include Moderna, Bristol Myers Squibb, Gi
Aug 712 min read
EMA OPEN Framework 2026 Update: What Pharma and Regulatory Affairs Teams Need to Know
The EMA OPEN framework (Opening Procedures at EMA to Non-EU Authorities) allows the European Medicines Agency (EMA) to run near-concurrent scientific assessments of certain medicines alongside seven non-EU regulatory partners, while each authority keeps full independence over its own decision. Originally piloted for COVID-19 medicines in December 2020, it was expanded to a wider range of therapeutic areas on 20 July 2023 and remains the operational basis for cross-border coll
Aug 511 min read
GSK's £400m Cambridge Global Centre of Excellence: What the Investment Means for UK Life Sciences and Regulatory Affairs Careers
GSK's £400 million Cambridge investment will fund a new flagship research and development centre on the Cambridge Biomedical Campus, housing more than 1,000 scientists and replacing GSK's long-standing Stevenage site by 2029. Announced on 28 July 2026, the move forms part of a wider £1.9 billion cost-savings programme and is framed by the UK government as evidence that its Modern Industrial Strategy is attracting investment into life sciences. For regulatory affairs professio
Jul 3112 min read
Why 90% of Regulatory Affairs Applicants Get Zero Job Offers (And How to Be the 10%)
Most regulatory affairs applicants never get an interview. Learn why — and the specific CV, experience and training fixes that put you in the top 10%. The overwhelming majority of regulatory affairs job applications fail before a human ever reads the covering letter. This article explains what happens to those applications, who typically gets rejected, why relevant scientific and clinical experience is routinely overlooked, and what separates the small minority of candidates
Jul 3112 min read
FDA Approves Tregzi (Orca-T) for GvHD Prophylaxis
The US Food and Drug Administration (FDA) approved Tregzi (Orca-T) on 30 June 2026, making it the first regulatory T cell-based immunotherapy authorised to improve chronic graft-versus-host disease (cGvHD)-free survival in adults undergoing matched donor allogeneic haematopoietic stem cell transplantation (allo-HSCT) for haematological malignancies. Developed by Orca Biosystems, Inc. (Orca Bio), Tregzi combines purified haematopoietic stem and progenitor cells (HSPCs), regula
Jul 2812 min read
10 Clinical Trials to Watch in H2 2026: From Lung Cancer Immunotherapy to Personalised Cancer Vaccines — A Regulatory Affairs Briefing
The most closely watched clinical trials to watch in H2 2026 span lung cancer immunotherapy, personalised mRNA cancer vaccines, obesity drugs, rare neuromuscular disease and novel anticoagulants, according to industry tracking from BioPharma Dive. These trials affect oncologists, biotech investors, sponsors and regulatory affairs teams preparing dossiers across the FDA, EMA and MHRA. Readouts expected between July and December 2026 will shape marketing authorisation strategy,
Jul 1012 min read
FDA Approves Lumvoa (Veligrotug-vvze) for Thyroid Eye Disease — What Regulatory Affairs Professionals Need to Know
The US Food and Drug Administration (FDA) approved Lumvoa (veligrotug-vvze) on 26 June 2026, making it the first therapy indicated for both active and chronic thyroid eye disease (TED). Developed by Viridian Therapeutics, Lumvoa is a full antagonist of the insulin-like growth factor-1 receptor (IGF-1R), delivered as five intravenous infusions over 12 weeks — a shorter course than the existing standard of care. Approval was supported by the pivotal Phase 3 THRIVE and THRIVE-2
Jul 812 min read
MHRA and UK Space Agency Establish the World's First Regulatory Pathway for In-Orbit Pharmaceutical Manufacturing — Roadmap Due Autumn 2026
The UK has published the world's first regulatory pathway for space-manufactured medicines. Learn what the MHRA and UK Space Agency announced and what it means for regulatory professionals. The meeting point between the global space economy and the pharmaceutical industry has been building for decades. Since the first protein crystallisation experiments aboard the International Space Station (ISS) in the early 2000s, researchers have understood that microgravity — the near-we
Jul 218 min read
50 Applications. Zero Interviews. Then One Course Changed Everything.
Part of the Entry to Regulatory Success Stories Series Prabhjot Malhi spent almost five years in Quality Control, applied to over 50 regulatory affairs roles across a full year, and received not a single interview. This is the story of how she went from a 0% success rate to a Senior Regulatory Affairs Specialist offer at Amgen — and what it took to get there. A Year of Applications. Not One Response. There is a specific kind of professional frustration that doesn't get talked
Jun 1811 min read